Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C26H41NO |
| Molecular Weight | 383.6098 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC\C=C/C\C=C/CCCCCCCC(=O)NC(C)C1=CC=CC=C1
InChI
InChIKey=RWIUTHWKQHRQNP-NQLNTKRDSA-N
InChI=1S/C26H41NO/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20-23-26(28)27-24(2)25-21-18-17-19-22-25/h7-8,10-11,17-19,21-22,24H,3-6,9,12-16,20,23H2,1-2H3,(H,27,28)/b8-7-,11-10-
DescriptionCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3214468 and http://www.ncbi.nlm.nih.gov/pubmed/3214468
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3214468 and http://www.ncbi.nlm.nih.gov/pubmed/3214468
Melinamide is an antilipidemic agent similar to gemfibrozil. It acts to lower elevated serum lipids by reducing the very low-density lipoprotein fraction rich in triglycerides. Serum cholesterol may be decreased, particularly in those patients whose cholesterol elevation is due to the presence of IDL as a result of Type III hyperlipoproteinemia.
Melinamide caused a decrease of the enhanced intestinal ACAT activity in diabetic rats, but did not affect intestinal cholesterol esterase activity. Marked improvement of hypercholesterolaemia in cholesterol-fed diabetic rats occurred concomitantly with the drug treatment. These results suggest that intestinal ACAT activity is closely related to the serum cholesterol level in diabetic rats, and show that melinamide lowers intestinal ACAT activity. Melinamide (Artes®) was the only marketed (in Japan) ACAT inhibitor. 04 Aug 2004 was withdrawn for Hypercholesterolaemia in Japan.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2265 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7887979 |
3.2 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Artes Approved UseHypercholesterolaemia |
PubMed
| Title | Date | PubMed |
|---|---|---|
| N-[2-[N'-pentyl-(6,6-dimethyl-2,4-heptadiynyl)amino]ethyl]- (2-methyl-1-naphthylthio)acetamide (FY-087). A new acyl coenzyme a:cholesterol acyltransferase (ACAT) inhibitor of diet-induced atherosclerosis formation in mice. | 1995-03-01 |
|
| In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. | 1993-02 |
|
| Contribution of peroxisomal beta-oxidation system to the chain-shortening of N-(alpha-methylbenzyl)azelaamic acid in rat liver. | 1990-06-15 |
|
| Cholesterol-lowering effect of N-(alpha-methylbenzyl)linoleamide (melinamide) in cholesterol-fed diabetic rats. | 1988-08 |
|
| Influence of 5-tridecylpyrazole-3-carboxylic acid, a new hypolipidaemic agent, on cholesteryl ester formation in rabbit intestinal mucosa. | 1988-07 |
|
| Inhibitory effect of melinamide on cholesterol solubility in mixed micellar solution of sodium taurocholate. | 1986-10 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2904986
Melinamide significantly inhibited ACAT in the range of 20 to 100 uM
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C471
Created by
admin on Mon Mar 31 18:37:21 GMT 2025 , Edited by admin on Mon Mar 31 18:37:21 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
JJ07049A84
Created by
admin on Mon Mar 31 18:37:21 GMT 2025 , Edited by admin on Mon Mar 31 18:37:21 GMT 2025
|
PRIMARY | |||
|
m7160
Created by
admin on Mon Mar 31 18:37:21 GMT 2025 , Edited by admin on Mon Mar 31 18:37:21 GMT 2025
|
PRIMARY | Merck Index | ||
|
20054967
Created by
admin on Mon Mar 31 18:37:21 GMT 2025 , Edited by admin on Mon Mar 31 18:37:21 GMT 2025
|
PRIMARY | |||
|
14417-88-0
Created by
admin on Mon Mar 31 18:37:21 GMT 2025 , Edited by admin on Mon Mar 31 18:37:21 GMT 2025
|
PRIMARY | |||
|
C87732
Created by
admin on Mon Mar 31 18:37:21 GMT 2025 , Edited by admin on Mon Mar 31 18:37:21 GMT 2025
|
PRIMARY | |||
|
DTXSID9048809
Created by
admin on Mon Mar 31 18:37:21 GMT 2025 , Edited by admin on Mon Mar 31 18:37:21 GMT 2025
|
PRIMARY | |||
|
2993
Created by
admin on Mon Mar 31 18:37:21 GMT 2025 , Edited by admin on Mon Mar 31 18:37:21 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104478
Created by
admin on Mon Mar 31 18:37:21 GMT 2025 , Edited by admin on Mon Mar 31 18:37:21 GMT 2025
|
PRIMARY | |||
|
20917-22-0
Created by
admin on Mon Mar 31 18:37:21 GMT 2025 , Edited by admin on Mon Mar 31 18:37:21 GMT 2025
|
SUPERSEDED | |||
|
100000081467
Created by
admin on Mon Mar 31 18:37:21 GMT 2025 , Edited by admin on Mon Mar 31 18:37:21 GMT 2025
|
PRIMARY | |||
|
C001757
Created by
admin on Mon Mar 31 18:37:21 GMT 2025 , Edited by admin on Mon Mar 31 18:37:21 GMT 2025
|
PRIMARY | |||
|
SUB08724MIG
Created by
admin on Mon Mar 31 18:37:21 GMT 2025 , Edited by admin on Mon Mar 31 18:37:21 GMT 2025
|
PRIMARY | |||
|
1674
Created by
admin on Mon Mar 31 18:37:21 GMT 2025 , Edited by admin on Mon Mar 31 18:37:21 GMT 2025
|
PRIMARY |
ACTIVE MOIETY